| Literature DB >> 28357784 |
Agathe Bronikowski1,2, Peter-Leon Hagedoorn3, Katja Koschorreck1,2, Vlada B Urlacher4,5.
Abstract
Laccases have gained significant attention due to their emerging applications including bioremediation, biomass degradation and biofuel cells. One of the prerequisites for the industrial application of laccases is their sufficient availability. However, expression levels of recombinantly expressed laccases are often low. In this study Mrl2, a new laccase from the basidiomycete Moniliophthora roreri, was cloned in Pichia pastoris and produced in an optimized fed-batch process at an exceptionally high yield of 1.05 g l-1. With a redox potential of 0.58 V, Mrl2 belongs to mid-redox potential laccases. However, Mrl2 demonstrated high kcat values of 316, 20, 74, and 36 s-1 towards 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS), syringaldazine (SGZ), 2,6-dimethoxyphenol (2,6-DMP) and guaiacol, respectively. Mrl2 remained stable above pH 6 and in the presence of many metal ions, which is important for application in bioremediation. Mrl2 was investigated for the ability to degrade endocrine disrupting chemicals (EDCs) and non-steroidal anti-inflammatory drugs (NSDAIs) at neutral pH value. The enzyme accepted and converted estrone, 17β-estradiol, estriol, the synthetic contraceptive 17α-ethinyl estradiol and bisphenol A at pH 7 faster than high-potential laccases from Trametes versicolor. For example, within 30 min Mrl2 removed more than 90% bisphenol A, 17ß-estradiol, 17α-ethinyl estradiol and estriol, respectively. The concentration of the recalcitrant drug diclofenac dropped by 56% after 20 h incubation with Mrl2.Entities:
Keywords: Expression; Laccase; Micropollutant degradation; Pichia pastoris
Year: 2017 PMID: 28357784 PMCID: PMC5371579 DOI: 10.1186/s13568-017-0368-3
Source DB: PubMed Journal: AMB Express ISSN: 2191-0855 Impact factor: 3.298
Chemical structures of endocrine disrupting chemicals and nonsteroidal anti-inflammatory drugs investigated in this study
| Endocrine disrupting chemicals (EDCs) | |||
| E1 |
| E2 |
|
| EE2 |
| E3 |
|
| BPA |
| BPS |
|
| Nonsteroidal anti-inflammatory drugs (NSAIDs) | |||
| Diclofenac | Naproxen | ||
| |
| ||
E1 estrone, E2 17ß-estradiol, EE2 17α-ethinyl estradiol, E3 estriol, BPA bisphenol A, BPS bisphenol S
Residual activity of Mrl2 towards ABTS in presence of different metal ions, cosolvents and inhibitors
| Metal ions | Residual activity (%) | Cosolvent | Residual activity (%) | Inhibitor | Concentration | Residual activity (%) | ||
|---|---|---|---|---|---|---|---|---|
| 10 mM | 100 mM | 10% | 20% | |||||
| Mn2+ | 99.3 ± 1.9 | 119.4 ± 3.8 | Ethanol | 81.9 ± 1.5 | 21.7 ± 2.4 | SDS | 0.1% | 100.3 ± 0.7 |
| Co2+ | 100.9 ± 0.9 | 104.6 ± 2.9 | Methanol | 76.5 ± 2.7 | 39 ± 0.8 | 1% | 77.7 ± 1.1 | |
| Ni2+ | 82.7 ± 1.5 | 26.2 ± 0.9 | 2-Propanol | 61.9 ± 2.5 | 5.5 ± 2.5 | |||
| Ca2+ | 85.4 ± 1 | 50.4 ± 1.9 | ACN | 52 ± 2.8 | 0.7 ± 0.4 | Sodium azide | 0.1% | 3.3 ± 1.9 |
| Cu2+ | 104.9 ± 2.5 | 95.2 ± 2.7 | DMSO | 22.9 ± 2.2 | 26.1 ± 3.6 | |||
| Na+ | 99 ± 2.8 | 105.1 ± 4.4 | Acetone | 22.2 ± 2 | 16.6 ± 2.3 | Cl | 10 mM | 37.3 ± 0.9 |
| Mg2+ | 101.5 ± 1.5 | 80.1 ± 1.7 | DMF | 40.2 ± 4.3 | 16.6 ± 0.4 | 50 mM | 12.2 ± 0.15 | |
| Zn2+ | 104.9 ± 2.1 | 97.0 ± 1.2 | Glycerol | 85.7 ± 0.5 | 89.7 ± 1.9 | 100 mM | 6.7 ± 0.04 | |
ACN acetonitrile, DMSO dimethyl sulfoxide, DMF dimethylformamid
Fig. 112.5% SDS-PAGE of Mrl2 purification. 5 µg total protein was loaded in each lane; M pre-stained protein markers; a Coomassie staining; 1 Mrl2 after DEAE FF purification, 2 Mrl2 after DEAE FF purification and PNGase F (indicated by an arrow) treatment, b zymogram with ABTS 1 purified Mrl2
Fig. 2pH optimum of Mrl2 in reactions with the substrates ABTS, SGZ, 2,6-DMP and guaiacol. The highest measured activity for each substrate was set to 100%
Km and kcat values of Mrl2 with ABTS, SGZ, 2,6-DMP and guaiacol at their corresponding pH optima
| Km (µM) | kcat (s−1) | kcat Km−1 (µM−1 s−1) | |
|---|---|---|---|
| ABTS | 24.13 ± 1.9 | 316 | 13.076 |
| SGZ | 12.45 ± 1.6 | 21 | 1.684 |
| 2,6-DMP | 358 ± 58.5 | 74 | 0.207 |
| Guaiacol | 2235 ± 117.5 | 37 | 0.016 |
Fig. 3Stability of Mrl2 at different pH values. After 1 h (black square), 3 h (white square), 8 h (black triangle) and 24 h (white triangle) incubation the residual activity (indicated in % of initial activity) was determined
Half-life of 500 µg ml−1 Mrl2 after incubation in 50 mM potassium phosphate buffer, pH 7 at different temperatures
| Temperature (°C) | Half-life |
|---|---|
| 20 | 13 days |
| 30 | 3 days |
| 40 | 12.5 h |
| 50 | 59 min |
| 60, 70, 80 | <1 min |
Fig. 4Residual quantity of EDCs and NSAIDs (%) after 0.5, 1 and 20 h of incubation with 20 U ml−1 Mrl2 at room temperature in 50 mM potassium phosphate buffer, pH 7. Measurements were carried out in triplicate
Fig. 5Residual quantity of EDCs and NSAIDs (%) after incubation with 30 µg ml−1 Mrl2 or TvL. The reaction time was set to 1 h except for DCF, for which it was 24 h. Measurements were carried out in triplicate
Comparison of reported laccase yields and volumetric activity in different expression hosts
| Source | Expression host | Laccase | Yield (mg l−1) | Vol. activity (U l−1) | Reference |
|---|---|---|---|---|---|
| Heterologous expression in yeast | |||||
|
|
| 2.8 | Bohlin et al. ( | ||
|
|
| lac3 | 41.5 | Kim et al. | |
|
|
| 146 | Bleve et al. ( | ||
|
|
| 3 | 168 | Kiiskinen and Saloheimo ( | |
|
|
| 227.9 | Lu et al. | ||
|
|
| LacMP | 232 | Liu et al. ( | |
|
|
| MaL | 7 | 270 | Andberg et al. ( |
|
|
| 580 | 685.8 | You et al. ( | |
|
|
| 19.84 | 1024 | Madzak et al. ( | |
|
|
| YlLac | 1290 | Kalyani et al. ( | |
| |
| CotA | 1648.15 | Wang et al. | |
|
|
| GwLac1 | 2260 | Zhou et al. | |
|
|
| Lcc1 | 17 | 2520 | Colao et al. ( |
|
|
| 517 | 3220 | Kittl et al. ( | |
|
|
| rLac1 | 3460 | Huang et al. ( | |
|
|
| 5406 | Zheng et al. | ||
|
|
| lacA | 4 | 5470 | Hong et al. ( |
|
|
| 9.03 | 5950 | Liu et al. | |
|
|
| LacTT | 1200 | 6130 | Liu et al. ( |
|
|
| Lac1 | 19.3 | 6300 | Yang et al. ( |
|
|
| lac4 | 110 | 10,200 | Soden et al. ( |
|
|
| 12,600 | Guo et al. | ||
|
|
| lccA | 18,123 | Li et al. | |
|
|
| 495 | 51,000 | Kittl et al. ( | |
|
|
| 140,000 | Hong et al. ( | ||
|
|
| 136 | 239,000 | Zhou et al. | |
|
|
| 8 | Otterbein et al. ( | ||
|
|
| 18 | Bulter et al. ( | ||
| Heterologous expression in filamentous fungi | |||||
|
|
| 2700 | Bohlin et al. | ||
|
|
| 3000 | Hoshida et al. | ||
|
|
| 3000 | Abianova et al. ( | ||
|
|
| r-MtL | 19 | Berka et al. | |
|
|
| 20 | Saloheimo and Nikupaavola ( | ||
|
|
| 70 | Record et al. | ||
|
|
| 920 | Kiiskinen et al. ( | ||
|
|
| 800–1000 | Baker and White ( | ||
| Heterologous expression in bacteria | |||||
|
|
| CotA | 373,100 | Guan et al. | |
| Natural production host | |||||
|
|
| Tvlac | 10,000 | Chen et al. ( | |
|
|
| rLacB | 31.6 | 32,000 | Li et al. |
|
|
| 65,000 | Galhaup and Haltrich ( | ||
|
|
| 85,000 | Hess et al. | ||
|
|
| Lcc3 | 200 | 202,000 | Chen et al. |
|
|
| LacA | 108 | 210,800 | Yang et al. |
| White rot fungus WR-1 | White rot fungus WR-1 | 692,000 | Revankar and Lele ( | ||